Key result
Curcumin intake (80 mg/day) for 24 weeks did not significantly affect mean levels of left (P=0.83) or right (P=0.47) CIMT, or PWV (P=0.12) compared to placebo in diabetic hemodialysis patients.
Why the study?
Prior studies reported curcumin is inversely associated with reduced atherosclerosis risk markers, but its effects on CIMT and PWV in diabetic hemodialysis patients had not been assessed.
Does curcumin improve carotid intima-media thickness and pulse wave velocity in diabetic hemodialysis patients?
RCT (n=39)
Double-blinded
Randomized
Does curcumin improve carotid intima-media thickness and pulse wave velocity in diabetic hemodialysis patients?
p-value: p=0.83
Curcumin supplementation at 80 mg/day for 24 weeks did not significantly improve markers of atherosclerosis risk (CIMT, PWV) or inflammation (CRP) in diabetic hemodialysis patients compared to placebo.
Curcumin yields no vascular benefit in diabetic hemodialysis patients; challenges assumptions of efficacy and supports avoiding routine supplementation.
Background: Prior studies have reported that curcumin is inversely associated with reduced markers of atherosclerosis risk, including carotid intima-media thickness (CIMT). This study was designed to assess the effects of curcumin on CIMT and pulse wave velocity (PWV) in diabetic hemodialysis (HD) patients. Methods: This randomized, double-blinded, placebo-controlled trial was conducted on 39 diabetic HD patients. People were assigned to receive curcumin or placebo (starch) for 24 weeks. Individuals in the curcumin group ( n = 26) received 80 mg/day. CIMT and PWV levels were taken at baseline and after 24 weeks of intervention. Results: After 24 weeks of intervention, curcumin intake did not affect mean levels of left ( P = 0.83) and right ( P = 0.47) CIMT and maximum levels of left ( P = 0.84) and right ( P = 0.11) CIMT, and PWV (P = 0.12) compared to the placebo. Furthermore, within-group difference demonstrated a significant reduction in mean levels of PWV ( P = 0.01) in the curcumin group. We did not observe any significant change in C-reactive protein (CRP) concentrations after curcumin intake ( P = 0.69). Conclusions: Curcumin intake did not affect mean levels of left and right CIMT and maximum levels of left and right CIMT, PWV, and CRP levels compared to the placebo. Additionally, within-group difference demonstrated a significant reduction in mean levels of PWV in the curcumin group. This trial was registered at www.irct.ir as http://www.irct.ir: IRCT20200527047584N1.
No takes yet. Share an insight, caveat, or question.
Ghasemiadl et al. (2024) conducted an RCT in Diabetic hemodialysis (n=39). Curcumin vs. Placebo (starch) was evaluated on Mean levels of left carotid intima-media thickness (CIMT) (p=0.83). Curcumin intake (80 mg/day) for 24 weeks did not significantly affect mean levels of left (P=0.83) or right (P=0.47) CIMT, or PWV (P=0.12) compared to placebo in diabetic hemodialysis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: